Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 8

Glucose metabolism and oncogenes in cancer

Pages
1605–1610
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The differences in metabolism of cancer cells are important targets for new treatment methods.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer cells utilize glucose quite differently from regular cells as cancer cells metabolize glucose more in aerobic glycolysis rather than in oxidative phosphorylation.
📊
Key Findings & Data:Results of increased glycolysis are quick production of ATP and intermediates for biosynthetic pathways and occur acidic cell environment.
💡
Conclusion & Impact:The differences in metabolism of cancer cells are important targets for new treatment methods.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cancer cells utilize glucose quite differently from regular cells as cancer cells metabolize glucose more in aerobic glycolysis rather than in oxidative phosphorylation. Whereas aerobic glycolysis is less effective in the metabolism than oxidative phosphorylation. This review aims to explain the mechanisms of cancer metabolism and recent findings related to the subject. There are excessive glycolysis and glucose transport in tumor cells, this situation as known Warburg effect. Mitochondrial impairment, hypoxia, oncogenic signals, and defected metabolic enzymes are mechanisms of this cancer metabolism. Results of increased glycolysis are quick production of ATP and intermediates for biosynthetic pathways and occur acidic cell environment. The oncogenes, hypoxiainducible factor (HIF), serine/threonine kinase Akt, K-ras, c-myc, AMP-activated protein kinase (AMPK) and p53 have important roles in cancer metabolism. HIF, Akt, K-ras, c-myc, AMPK, and p53 are important oncogenes in cancer metabolism. The differences in metabolism of cancer cells are important targets for new treatment methods.

🔖

Cite This Article

MERTOĞLU, C. (2022). Glucose metabolism and oncogenes in cancer. Annals of Medical Research, Cilt: 28 - Sayı: 8, 1605–1610. https://ajindex.com/articles/445776

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Murray RK, Davis JC. Harper’s Illustrated Biochemistry 30th Edition. Molecular Physiology 2014:738-39 2. Warburg O. On the origin of cancer cells. Science1956
  2. Voet D, Voet JG. Pyruvate Dehydrogenase Multienzyme Complex. Biochem 2nd Ed 1995
  3. Liberti M V., Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci 2016
  4. Farwell MD, Pryma DA, Mankoff DA. PET/CT imaging in cancer: Current applications and future directions. Cancer 2014
  5. López-Ríos F, Sánchez-Aragó M, García-Garía Eet al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007
  6. Heiden MGV, Cantley LC, Thompson CB. Understanding the warburg effect: The metabolic requirements of cell proliferation. Science 2009
  7. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature Reviews Cancer. 2004
  8. Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species 1. FASEB J 1997
  9. Yecies JL, Manning BD. Chewing the Fat on Tumor Cell Metabolism. Cell 2010
  10. Nomura DK, Long JZ, Niessen S et al. Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis. Cell 2010
  11. Sawayama H, Ishimoto T, Watanabe M et al. High expression of glucose transporter 1 on primary lesions of esophageal squamous cell carcinoma is associated with hematogenous recurrence. Ann Surg Oncol 2014
  12. Goodwin J, Neugent ML, Lee SYet al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun 2017
  13. 15503. 14. Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J Biol Chem 1995
  14. 29083-9. 15. Haber RS, Rathan A, Weiser KR et al. GLUT1 glucose transporter expression in colorectal carcinoma: A marker for poor prognosis. Cancer 1998
  15. Goos JACM, De Cuba EMV, Coupé VMH et al. Glucose transporter 1 (SLC2A1) and vascular endothelial growth factor A (VEGFA) predict survival after resection of colorectal cancer liver metastasis. Ann Surg 2016
  16. Hiyoshi Y, Watanabe M, Imamura Y et al. The relationship between the glucose transporter type 1 expression and 18F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Onco